|
|
|
Esperoct® is used to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A.
See full indication below. |
|
|
|
|
| “Growing up, my condition continued to progress. It was hard. I was always in pain. I started on Esperoct® in 2020…I wanted a product that could travel with me everywhere I go. One of the things I really love about Esperoct® is the flexibility it gives you. Managing my care with my doctor and identifying a treatment that works for me has made a difference in reducing the frequency of my bleeding episodes.” |
| Individual results may vary. |
|
|
|
|
| Selected Important Safety Information |
| Who should not use Esperoct®? |
| |
• |
You should not use Esperoct® if you are allergic to factor VIII or
any of the other ingredients of Esperoct® or if you are allergic to
hamster proteins
|
|
|
What is the most important information I need to know about Esperoct®?
|
| |
• |
Do not attempt to do an infusion yourself unless you have been taught how by
your healthcare provider or hemophilia treatment center
|
|
| |
• |
Call your healthcare provider right away or get emergency treatment right away
if you get any signs of an allergic reaction, such as:
hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling
of the face
|
|
|
Please
click here
or scroll below for additional Important Safety Information.
|
|
|
|
| To find the right treatment for his severe hemophilia A, Bradley worked with his doctors and support system, did his own research, and asked a lot of questions. His local Hemophilia Community Liaison (HCL) provided all the information he wanted about Esperoct®. |
| Since he made the switch, his HCL has continued to be a great resource for connecting Bradley to local events, providing lifestyle tips, and more. |
|
|
|
|
|
| Your Esperoct® story matters and we want to highlight it in a big way! Sharing your experiences with hemophilia A and successfully treating with Esperoct® could inspire others in the bleeding disorders community. |
|
|
|
|
| What is Esperoct®? |
| Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery |
| |
• |
Esperoct® is not used to treat von Willebrand Disease |
|
| Important Safety Information (cont’d) |
| What should I tell my healthcare provider before using Esperoct®? |
| |
• |
Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII |
| |
• |
Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct® |
|
| What are the possible side effects of Esperoct®? |
| |
• |
Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion |
|
| Please click here for Prescribing Information. |
| Esperoct® is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. |
| Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-877-744-2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22ESP00025 August 2022 |
 |
|
|
|
